Izindaba Zemboni
Isinyathelo sokuqala se-CAR-T Commercialization
Njengendlela entsha ye-tumor immunotherapy, i-CAR-T I-Cell Therapy ibonise amandla amakhulu okwelapha. Nokho, ukusebenza kwezohwebo kusho izinselelo ezintsha. Uma kuqhathaniswa namakhemikhali endabuko, i-biopharmaceuticals "ephilayo" inokungaqiniseki okukhulu, izinkinga ezingaba khona...
Umphumela we-interleukin emsebenzini wamaseli e-NK (IL-1β, IL-12, IL-15, IL-18, IL-21)
Amaseli abulalayo emvelo avela kumaseli e-bone marrow lymphoid stem futhi angamaseli azalwa namasosha omzimba emzimbeni. Aqanjwe ngamagama angaqondile we-cytotoxicity. Umsebenzi wokubulala we Nk Cells ayinqunyelwe yi-MHC futhi ayincikile kumasosha omzimba, yingakho ibizwa ngokuthi umsebenzi wokubulala wemvelo.
Isifinyezo Sezici Zamaprotheni Ezihilelekile Kusiko Leseli Le-Hematopoietic Stem
Eminyakeni yamuva nje, ama-stem cells asesetshenziswa kabanzi ekusetshenzisweni komtholampilo. Kodwa-ke, inani kanye nenani lama-stemcells emzimbeni womuntu liphansi kakhulu, elingakwazi ukuhlangabezana nezidingo zomtholampilo.
Overseas Exhibition Preview | I-T&L izobamba iqhaza ku-SITC 2023 San Diego, USA
Ingqungquthela Yonyaka Ye-38th Society for Immunotherapy of Cancer (SITC) izobanjwa kusukela ngoNovemba 1-5 eSan Diego, e-USA.
![[Blockbuster] T&L CGT core izinto zokusetshenziswa zibhaliswe kabusha ne-US FDA DMF](https://ecdn6-nc.globalso.com/upload/p/1757/image_product/2024-06/news1.jpg)
[Blockbuster] T&L CGT core izinto zokusetshenziswa zibhaliswe kabusha ne-US FDA DMF
Siyajabula ukumemezela ukuthi ngemva kokuthola ukubhaliswa kwe-DMF kwe-CD3 monoclonal antibody kanye ne-CD3/CD28 yokuhlunga ubuhlalu obuzibuthe obucushiwe, imikhiqizo yezinga le-T&L's GMP, amaprotheni e-IL-7 womuntu aphinde ahlanganiswe (Cat. No. GMP-TL506) ...